|Bid||26.01 x 200|
|Ask||26.25 x 100|
|Day's range||25.88 - 26.28|
|52-week range||7.17 - 27.33|
|PE ratio (TTM)||N/A|
|Earnings date||1 Feb 2017 - 6 Feb 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.00|
Stocks with market capitalization between $2B and $10B, such as Immunomedics Inc (NASDAQ:IMMU) with a size of US$4.32b, do not attract as much attention from the investing community as doRead More...
Two weeks ago, B. Riley analyst Madhu Kumar gushed about Immunomedics, writing in a report that the biotech could have a “blockbuster cancer drug” in IMMU-132, an antibody-drug conjugate that had shown promise in disrupting “multiple solid cancers.” Kumar initiated coverage of the biotech on June 6 at Buy with a $53 price target. On Friday, Immunomedics (IMMU) Chairman Behzad Aghazadeh bought $18.5 million worth of the company’s stock through venBio Select Fund, a hedge fund where he serves as managing partner and portfolio manager. Aghazadeh bought 575,000 Immunomedics shares through the company’s public offering at $24 each, and went to the open market to buy another 200,000 shares for a better average per-share price of $23.39.
Immunomedics popped to an 18-year high Monday after it unveiled plans for its cancer drug, including a tie-up with Clovis Oncology to test a regimen.
Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 21 cents. Losses, adjusted for non-recurring costs, were 14 cents per share. The biopharmaceutical company posted ...
Biotechnology stocks dominate our list of top charts to watch, with a uranium producer also advancing to the list. CASI Pharmaceuticals Inc.(CASI) rose 48 cents, or 7.2%, to $7.14 on 773,700 shares traded Tuesday. The move came on no news from the company, although the stock soared in early April on news that China’s Food and Drug Administration (CFDA) would convene a panel to discuss its cancer therapy, Evomela.
The Morris Plains, New Jersey-based company said it had a loss of 2 cents per share. Losses, adjusted for non-recurring gains, came to 19 cents per share. The biopharmaceutical company posted revenue of ...
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 97 cents. Losses, adjusted for non-recurring costs, were 16 cents per share. The results fell short of Wall Street ...
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.